1 year ago
The Total Remission Rate of CAR-T Hodgkin Lymphoma Was 78% • Classical Hodgkin lymphoma (cHL) is a malignant lymphoid disease and the most common subtype of lymphoma. Statistics show that about 93,...
1 year ago
**IASO Bio’s Equecabtagene Autoleucel Injection Wins “China First-in-Class” Award, Showcasing China’s Biopharmaceutical Innovation** Multiple myeloma On June 28, 2024, at ...
1 year ago
The First Human Trial of Autologous CD5.CAR-T for T Cell Lymphoma Without Gene Editing T cell lymphomas (TCLs) are more challenging hematologic malignancies compared to B cell lymphomas. Despite re...
1 year ago
CAR-T for Mantle Cell Lymphoma CAR-T Therapy for MCL Mantle cell lymphoma (MCL) is a subtype of mature B-cell non-Hodgkin lymphoma (NHL) characterized by a chromosomal translocation, typically resu...
1 year ago
CAR-T for Follicular Lymphoma: Lisocabtagene Maraleucel Offers Durable Remission Follicular lymphoma is a lymphoproliferative disorder of B-cell origin. It is a type of non-Hodgkin lymphoma, with o...
1 year ago
**2024 ASCO: National Institute’s New CAR-T Therapy CD7 CAR-T Cells, Multiple Blood Cancer Destroyers** CAR-T Therapy **2024 ASCO: Four Chinese-developed CAR-T therapies make a significant im...
1 year ago
Progress and Thinking of CAR-T for DLBCL Treatment Exploration never stops, and the grand meeting is just around the corner. From January 26 to 28, 2024, the “Working Conference of the Leukem...
1 year ago
CAR-T Follicular Lymphoma Approval Yescarta(Axicabtagene Ciloleucel) – In October 18, 2017, the FDA approved Yescarta(Axicabtagene Ciloleucel), a CAR T-cell therapy, for the treatment of rela...
1 year ago
Phase 2 Clinical Study of Lisocabtagene Maraleucel (liso-cel) CAR-T Follicular Lymphoma with More Than 2 Lines of Treatment CAR-T Therapy for Follicular Lymphoma For patients with relapsed/refracto...
1 year ago
CAR-T DLBCL Approval: A Comprehensive Overview Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin’s lymphoma, accounting for approximately 30% of all newly diagnosed c...
1 year ago
**2024 ASCO China Highlights: China’s Indigenous TIL Therapy Makes a Strong Debut, Targeting Small Cell Lung Cancer, Melanoma, Cervical Cancer, with a DCR Over 90%** **GT101: Targeting Mul...
1 year ago
Successful Cases of CAR-T Diffusion Large B Cell Lymphoma in the Treatment of Advanced Patients “CR Dawn” is a column launched by Lymphoma Home, aimed at sharing the recovery stories of...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
